ArticleOphthalmology and therapy2026
Beyond Vision: Prospective Real-World Evaluation of Quality-of-Life and Caregiver Burden in Diabetic Macular Edema Treated with Fluocinolone Acetonide (Iluvien
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiabetic macular edema (DME) imposes a substantial clinical and psychosocial burden on patients and caregivers due to frequent visits and intravitreal treatments. The fluocinolone acetonide intravitreal implant (Iluvien
methodsProspective, real-world observational study of 41 patients with previously treated DME. Assessments occurred at baseline and at 6, 12, 18, 24, and 30 months. Outcomes included best-corrected visual acuity (BCVA), central macular thickness (CMT), IOP, and National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) composite scores. Burden metrics included clinic visits per year and caregiver accompaniment/absenteeism.
resultsAt baseline, mean BCVA was 0.42 ± 0.30 logMAR, CMT 415.8 ± 106.5 µm, IOP 16.6 ± 4.1 mmHg, and NEI VFQ-25 67.6 ± 16.4; 46.3% of patients required caregiver accompaniment, and 61% reported pre-injection anxiety (median duration 2 days). At last follow-up, mean BCVA improved to 0.29 ± 0.26 logMAR (≈+6-7 ETDRS letters; p < 0.001), CMT decreased to 368.1 ± 79.6 µm (p = 0.002), and IOP remained stable at 16.7 ± 4.1 mmHg. The NEI VFQ-25 increased to 77.0 ± 18.0, with a significant main effect of time (repeated-measures analysis of variance (ANOVA), p = 0.001; partial η
conclusionsIn a prospective real-world setting, Iluvien was associated with durable improvements in vision, macular anatomy, and QoL, with stable IOP. Treatment reduced the frequency of clinic visits and procedures, alleviating patient burden and caregiver absenteeism. These findings support Iluvien as a patient-centered, long-acting therapy for chronic DME and motivate multicenter validation and health-economic studies that incorporate caregiver outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.